All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Significant advances in antibody engineering have led to the development of a novel therapeutic class with a unique mechanism of action: to target both malignant cells and T cells and bring them closer together, activating the cytotoxic capacity of the immune cell. T-cell engagers include IgG-like bispecific antibodies and optimized designs without the Fc domain (BiTEs, DARTs, and TriKEs).